Partial orphan cancer drugs: FDA approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending

被引：0
|
作者：
Michaeli, D. T. [1 ]
Michaeli, C. T. [2 ]
机构：
[1] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany
[2] UMM Univ Klinikum Mannheim, Abteilung Personalisierte Onkol Schwerpunkt Lung, Mannheim, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2650
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1696MO
引用
收藏
页码：S927 / S927
页数：1
相关论文
共 50 条
  • [1] Partial Orphan Cancer Drugs: US Food and Drug Administration Approval, Clinical Benefit, Trials, Epidemiology, Price, Beneficiaries, and Spending
    Michaeli, Thomas
    Michaeli, Daniel Tobias
    VALUE IN HEALTH, 2024, 27 (04) : 449 - 457
  • [2] Breakthrough Therapy Cancer Drugs and Indications With FDA Approval: Development Time, Innovation, Trials, Clinical Benefit, Epidemiology, and Price
    Michaeli, Daniel Tobias
    Michaeli, Thomas
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (04):
  • [3] Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations
    Michaeli, Daniel Tobias
    Michaeli, Thomas
    Albers, Sebastian
    Michaeli, Julia Caroline
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2024, 116 (02): : 216 - 229
  • [4] Characteristics of Clinical Trials to Support Approval of Orphan vs Nonorphan Drugs for Cancer
    Kesselheim, Aaron S.
    Myers, Jessica A.
    Avorn, Jerry
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22): : 2320 - 2326
  • [5] Clinical Trials of Orphan Drugs for Cancer
    Saltonstall, Peter L.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (14): : 1545 - 1545
  • [6] Participation of African Americans in clinical trials supporting FDA approval of cancer drugs.
    Al Hadidi, Samer
    Mims, Martha P.
    Miller-Chism, Courtney Nicole
    Kamble, Rammurti T.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Efficacy, innovativeness, clinical trials, endpoints, and price of drugs with FDA approval for non-small cell lung cancer (NSCLC)
    Michaeli, C. T.
    Michaeli, J. C.
    Desai, A.
    Albers, S.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2024, 35 : S845 - S845
  • [8] Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015
    Vivot, A.
    Jacot, J.
    Zeitoun, J. -D.
    Ravaud, P.
    Crequit, P.
    Porcher, R.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1111 - 1116
  • [9] Spending on and beneficiaries of orphan cancer drugs for ultra-rare, rare, and common diseases
    Michaeli, J. C.
    Michaeli, C. T.
    Michaeli, D. T.
    ANNALS OF ONCOLOGY, 2023, 34 : S927 - S928
  • [10] Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price
    Michaeli, Julia Caroline
    Michaeli, Thomas
    Trapani, Dario
    Albers, Sebastian
    Dannehl, Dominik
    Wuerstlein, Rachel
    Michaeli, Daniel Tobias
    BREAST CANCER, 2024, 31 (06) : 1144 - 1155
12345